SCHEMBL3672206

SCHEMBL3672206

CCCC(C)NC(=O)c1ccc(N2CCN(C(=O)CC3CCCCC3)CC2)nc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 2/20 0.53
HSD17B10 Q99714 1/20 0.53
ENPP2 Q13822 3/20 0.44
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
USP30 Q70CQ3 2/20 0.43
HRH3 Q9Y5N1 4/20 0.42
SCD O00767 1/20 0.41
HPGDS O60760 1/20 0.40
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
RAB9A P51151 2/20 0.40
GPR119 Q8TDV5 1/20 0.40
NPC1 O15118 1/20 0.40
MCHR1 Q99705 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3675248 0.91 ENPP2 (0.50) ALDH1A1KDM4EENPP2HPGDSMN1; SMN2
SCHEMBL3674091 0.90 ALDH1A1 (0.53) ALDH1A1KDM4EHSD17B10ENPP2HPGD
SCHEMBL3672230 0.89 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10ENPP2HPGD
SCHEMBL3671178 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3674976 0.84 SCD (0.58) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3675479 0.84 ME2 (0.47) ALDH1A1ENPP2HPGDSMN1; SMN2USP30
SCHEMBL3672147 0.83 ALDH1A1 (0.53) ALDH1A1KDM4EHSD17B10ENPP2HPGD
SCHEMBL3668366 0.83 SCD (0.43) ALDH1A1KDM4EENPP2HPGDSMN1; SMN2
SCHEMBL3670096 0.82 ALDH1A1 (0.53) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3777220 0.81 HRH3 (0.47) ALDH1A1ENPP2HPGDSMN1; SMN2USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT ALDH1A1 1127/4885KDM4E 3385/4885HSD17B10 836/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 ALDH1A1 3898/4885KDM4E 4395/4885HSD17B10 3221/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT ALDH1A1 1127/4885KDM4E 3385/4885HSD17B10 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.